Consequently, the safest investment in the ESC field may be «something where you're an enabler of the technology» by providing the raw tools and
ingredients for ESC research, says Steve Brozak, an analyst with WBB Securities in San Diego, Calif. «The time frame [for ESCs] is now for drug discovery, soon for personalized medicine, and decades for
therapeutic use,»
adds Bob Palay, chairman and CEO of Cellular Dynamics International (CDI), a biotech company working with ESCs in Madison, Wisc..